Почетна › Рак на дојка › Вирџинија › Arlington
Клинички испитувања за Рак на дојка во Arlington, VA
46 студии за Рак на дојка бараат учесници на локации во и околу Arlington (во радиус од околу 30 милји). Отворете ја студијата за да видите кој може да учествува и како да го контактирате тимот.
Официјален текст на студијата (англиски)
Барате учесници за студија? Истакнете ја на врвот од оваа страница — $99 за 30 дена →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Се регрутираФаза 1/2
- Virginia Cancer Specialists, Fairfax · на 11 милји
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Се регрутираФаза 2
- Virginia Cancer Specialists, Fairfax · на 11 милји
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Се регрутираФаза 1/2
- Inova Schar Cancer Institute, Fairfax · на 11 милји
- Virginia Cancer Specialists, PC, Fairfax · на 11 милји
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
Се регрутираФаза 3
- Inova Schar Cancer Institute, Fairfax · на 11 милји
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
Се регрутираФаза 2
- Inova Schar Cancer Institute, Fairfax · на 11 милји
Study of AVZO-021 in Patients With Advanced Solid Tumors
Се регрутираФаза 1/2
- Avenzo Therapeutics Recruiting Site, Fairfax · на 11 милји
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Се регрутираФаза 3
- Inova Schar Cancer Institute ( Site 0025), Fairfax · на 11 милји
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Се регрутираФаза 3
- Research Site, Fairfax · на 11 милји
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Се регрутираФаза 2
- Virginia Cancer Specialists, Fairfax · на 11 милји
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Се регрутира
- Inova, Fairfax · на 11 милји
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Се регрутираФаза 3
- Virginia Cancer Specialists, Fairfax · на 11 милји
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Се регрутираФаза 2
- Inova Schar Cancer Institute, Fairfax · на 11 милји
A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
Се регрутираФаза 1
- Next Virginia, Fairfax · на 11 милји
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Се регрутираФаза 1/2
- NEXT Oncology, Fairfax · на 11 милји
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Се регрутираФаза 3
- Inova Schar Cancer Institute, Fairfax · на 11 милји
- Virginia Cancer Specialists, Fairfax · на 11 милји
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Се регрутираФаза 1
- Virginia Cancer Specialists, Fairfax · на 11 милји
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Се регрутираФаза 1
- NEXT Oncology - Virginia Cancer Specialists, Fairfax · на 11 милји
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Се регрутираФаза 1
- NEXT Oncology, Fairfax · на 11 милји
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Се регрутираФаза 1/2
- Virginia Cancer Specialists-Fairfax, Fairfax · на 11 милји
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Се регрутираФаза 1/2
- Next Oncology, Fairfax · на 11 милји
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Се регрутираФаза 3
- Virginia Cancer Specialists, PC, Fairfax · на 11 милји
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Се регрутираФаза 1/2
- NEXT Virginia, Fairfax · на 11 милји
The Vanguard Study: Testing a New Way to Screen for Cancer
Се регрутираДобредојдени се здрави волонтери
- Inova Schar Cancer Institute, Fairfax · на 11 милји
- Inova Fair Oaks Hospital, Fairfax · на 11 милји
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Се регрутираФаза 3
- Kaiser Permanente Tysons Corner Medical Center, McLean · на 5 милји
- Kaiser Permanente-Burke Medical Center, Burke · на 11 милји
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Се регрутираФаза 1
- NEXT Virginia, Fairfax · на 11 милји
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Се регрутираФаза 1
- NEXT Virginia, Fairfax · на 11 милји
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Се регрутираФаза 1
- Inova Schar Cancer Institute, Falls Church · на 4 милји
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Се регрутираФаза 3
- Inova Schar Cancer Institute, Fairfax · на 11 милји
- Inova Fair Oaks Hospital, Fairfax · на 11 милји
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Се регрутираФаза 3
- Virginia Cancer Specialists, Fairfax · на 11 милји
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Се регрутираФаза 1/2
- USOR Virginia Cancer Specialists, Fairfax · на 11 милји
E-Mindfulness Approaches for Living After Breast Cancer
Се регрутираФаза 3
- Inova Fairfax Hospital, Falls Church · на 4 милји
- Kaiser Permanente Tysons Corner Medical Center, McLean · на 5 милји
- Inova Schar Cancer Institute, Fairfax · на 11 милји
- и уште 1
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Се регрутираФаза 1
- NEXT Virginia, Fairfax · на 11 милји
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Се регрутираФаза 1/2
- USO-Virginia Cancer Specialists, PC, Fairfax · на 11 милји
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
Се регрутираФаза 3
- INOVA Schar Cancer, Fairfax · на 11 милји
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Се регрутираФаза 1/2
- NEXT Oncology Virginia, Fairfax · на 11 милји
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Се регрутираФаза 1/2
- NEXT, Fairfax · на 11 милји
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Се регрутираФаза 1/2
- Virginia Cancer Specialists, Fairfax · на 11 милји
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Се регрутираФаза 1/2
- Inova Schar Cancer Institute ( Site 0051), Fairfax · на 11 милји
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Се регрутираФаза 3
- Virginia Cancer Specialists, PC, Reston · на 14 милји
- Virginia Cancer Specialists, Manassas · на 22 милји
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
Се регрутираФаза 1
- Virginia Cancer Specialists, Fairfax · на 11 милји
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Се регрутираФаза 1
- NEXT Oncology Virginia, Fairfax · на 11 милји
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Се регрутираФаза 1/2
- NEXT Virginia, Fairfax · на 11 милји
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Се регрутираФаза 1/2
- Virginia Cancer Specialists, Fairfax · на 11 милји
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
Се регрутираФаза 1/2
- NEXT, Virginia, Fairfax · на 11 милји
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Се регрутираФаза 1
- Inova Schar Cancer Center, Fairfax · на 11 милји
- NEXT Virginia, Fairfax · на 11 милји
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer
Се регрутираФаза 1
- Biotheryx Investigative Site, Fairfax · на 11 милји
Испитувања за Рак на дојка во други градови
- New York City, NY134 студии
- Houston, TX126 студии
- Boston, MA111 студии
- Nashville, TN80 студии
- Los Angeles, CA72 студии
- Edison, NJ68 студии
- St. Louis, MO64 студии
- Durham, NC63 студии
- Queens, NY63 студии
- Chicago, IL58 студии
- Philadelphia, PA56 студии
- Dallas, TX55 студии
Други студии во Arlington
- Рак на бели дробови со не-мали клетки104 студии
- Метастатски карцином53 студии
- Колоректален карцином52 студии
- Рак (сите типови)48 студии
- Карцином на јајниците46 студии
- Рак на бели дробови41 студија
- Рак на ендометриумот39 студии
- Карцином на панкреасот33 студии
- Сквамозноклеточен карцином на глава и врат26 студии
- Малоклеточен рак на бели дробови23 студии
- Трипл негативен рак на дојка20 студии
- Рак на стомакот20 студии
Од ClinicalTrials.gov, податоци преземени 5.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.